InSite and Senju collaborate to develop and market azithromycin ophthalmic solution using DuraSite

InSite Vision Incorporated (OTCBB:INSV) and Senju Pharmaceutical Co., Ltd. today announced that they have entered into a collaboration and license agreement to develop and market InSite's azithromycin ophthalmic solution using DuraSite® including AzaSite® 1% and AzaSite XtraTM 2% ocular antibiotics in Japan. Senju has agreed to pay InSite an upfront license fee, additional development milestones fees, and a percentage royalty on net sales.

"We are pleased to enter this strategic partnership with one of the leading ophthalmic pharmaceutical companies in Japan," said Timothy Ruane, Chief Executive Officer of InSite Vision. "We look forward to the approval of these important ocular antibiotics for the benefit of the Japanese people."


Senju Pharmaceutical Co., Ltd.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
You might also like...
Using 3D-electron diffraction to determine the structure of Levocetirizine dihydrochloride